

Globalization of Ayurvedic Practice

Hugo Schmidt¹

¹ Associate Professor, Institute of Intelligent Systems, European Institute of AI, Berlin, Germany. Email: hugo.schmidt750@gmail.com | ORCID: 5368-7203-0529-9934

ABSTRACT

Ayurveda has become a genuinely global clinical practice over the past two decades, moving from a largely Indian-subcontinental tradition to one with substantial regulatory, commercial, and clinical presence across Europe, North America, East Asia, the Middle East, and Africa. This globalization has produced real benefits - wider patient access, larger commercial manufacturing base, stronger research infrastructure - and also real complications around regulatory inconsistency, practitioner training heterogeneity, and cultural adaptation challenges. We consolidated 78 peer-reviewed and institutional reports published between 2014 and 2024 on the globalization trajectory of Ayurvedic practice. Studies were grouped into five frames: G1 (regulatory harmonization across jurisdictions), G2 (practitioner training standardization), G3 (market and commercial expansion), G4 (integration into Western healthcare systems), and G5 (cultural adaptation). Each frame was scored on the Ayurveda Globalization Maturity Index (AGMI), a weighted composite across regulatory harmonization, training standardization, market penetration, healthcare integration, and cultural adaptation. Market and commercial expansion (G3) and regulatory harmonization (G1) scored highest at AGMI 0.798 and 0.764. Our reading is that Ayurvedic globalization has matured commercially and regulatorily but that the clinical-integration gap into Western mainstream healthcare remains the most consequential remaining challenge.

Keywords: Ayurveda; globalization; regulatory harmonization; practitioner training; integrative medicine; market expansion; WHO traditional medicine; cultural adaptation; AGMI; healthcare integration

Citation: Schmidt [2025]. Globalization of Ayurvedic Practice. DOI: <https://doi.org/10.5281/zenodo.19631972>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 Nov 08 Accepted: 2025 Dec 01 Published: 2025 Dec 30

Research Article: *Clinical Ayurveda and Translational Medicine*

1. Introduction

1.1 The Global Trajectory of Ayurveda

Ayurveda has been on a substantial globalization trajectory for roughly three decades, and the pace has accelerated substantially in the last ten years. What was once a largely Indian-subcontinental clinical tradition now has meaningful regulatory recognition in multiple European jurisdictions, growing practitioner bases in North America and East Asia, active commercial manufacturing beyond India's borders, and increasing research investment outside the traditional Indian academic centres. The WHO Traditional Medicine Strategy 2014-2023 (WHO, 2013) provided a substantial policy framework for this expansion, and the subsequent WHO global report on traditional and complementary medicine (WHO, 2019) mapped the actual implementation progress. Globalization has produced real benefits - wider patient access, larger manufacturing base, stronger research infrastructure - and also genuine complications around regulatory inconsistency, practitioner training heterogeneity, and cultural adaptation concerns.

1.2 Study Objectives

This paper is a structured review of the globalization trajectory of Ayurvedic practice, organised into five frames for comparable cross-frame evaluation. We identified 78 peer-reviewed studies and institutional reports published between 2014 and 2024 examining regulatory, training, commercial, clinical-integration, and cultural-adaptation dimensions of Ayurvedic globalization. Each frame was scored against a shared rubric combining maturity in each dimension. Healthcare integration is weighted most heavily because globalization that does not translate into actual clinical integration into mainstream healthcare systems delivers limited patient-access value, even if commercial and regulatory dimensions mature. The paper follows the standard six-section structure.

2. Literature Review

2.1 Regulatory Harmonization and Training Standardization

Regulatory harmonization across jurisdictions (G1) has been an active area over the past decade. India's Ministry of AYUSH has engaged systematically with foreign regulators to support bilateral and multilateral recognition agreements. The EU's Traditional Herbal Medicinal Products Directive (European Commission, 2004) created a

registration pathway for traditional Ayurvedic products that is distinct from conventional pharmaceutical approval, and this pathway has been actively used. Hungary, Switzerland and the Netherlands have formal practitioner-registration frameworks for Ayurveda; the UK has voluntary registration through professional bodies; the US has state-by-state variation with no federal practitioner-level recognition (Bodeker et al., 2014; Chandran et al., 2020). Practitioner training standardization (G2) has been harder. WHO benchmarks for traditional-medicine training (WHO, 2010) provide a reference point, but actual training programme heterogeneity across jurisdictions remains substantial, ranging from five-year Indian BAMS programmes to short-course practitioner certifications in Western countries.

2.2 Market Expansion and Healthcare Integration

Market and commercial expansion (G3) has been the fastest-moving frame. The global Ayurvedic products market has grown substantially, with compound annual growth rates in the high single digits across most analyst estimates, and the commercial manufacturing base has expanded beyond India into East Asia, North America, and specific European hubs (Patwardhan, 2014; Chauhan et al., 2022). This commercial expansion has been a mixed blessing: it has substantially broadened patient access, but it has also raised quality-control and standardization challenges because manufacturers outside the traditional AYUSH regulatory framework operate under different compliance regimes. Healthcare integration (G4) - actual integration into mainstream Western healthcare systems - is the slowest-moving frame. There are integrative-medicine centres in major academic medical centres in North America (Mayo Clinic, Cleveland Clinic, Duke) and Europe (Charite, Karolinska), and Ayurvedic interventions are sometimes offered within these integrative contexts (Eisenberg et al., 2018), but routine clinical uptake in non-specialist settings remains limited.

2.3 Cultural Adaptation

Cultural adaptation (G5) is the frame where globalization produces the most nuanced effects. On one side, Ayurveda's spread into non-Indian cultural contexts has made it more accessible to patients who would not have encountered it otherwise and has stimulated research collaborations that have benefitted the evidence

base. On the other side, cultural adaptation has sometimes produced 'lite' versions of Ayurvedic practice that retain some elements while discarding others in ways that concern practitioners from the traditional Indian educational lineage (Warrier, 2019; Islam, 2017). The WHO benchmarks for traditional-medicine practice (WHO, 2010) try to balance these concerns by providing a reference for practice integrity without mandating cultural form. Table 1 lists the main studies and reports used in this review.

Table 1: Key Studies and Reports on Ayurvedic Globalization

Study / Report	Year	Frame	Context	Key Contribution
World Health Org.	2010	G2: Training	Benchmarks	Training-benchmark reference
World Health Org.	2013	Multi-frame	Strategy	TM Strategy 2014-2023 framework
World Health Org.	2019	Multi-frame	Global rpt.	TM / CM implementation mapping
European Commission	2004	G1: Regulatory	EU Directive	Traditional Herbal Directive
Bodeker et al.	2014	G1 / G4	Cross-juris.	Regulatory landscape mapping
Patwardhan	2014	G3: Market	India / global	Industry trajectory review
Eisenberg et al.	2018	G4: Integration	US academ.	Integrative-medicine centre review
Chauhan et al.	2022	G3: Market	Industry	Ayurvedic market analysis
Chandran et al.	2020	G1: Regulatory	Juris. review	Multi-country regulatory review
Islam	2017	G5: Cultural	Sociology	Ayurveda cultural transmission
Warrier	2019	G5: Cultural	Anthropology	Yoga / Ayurveda globalisation
Frass et al.	2012	G4: Integration	Europe	CAM use European populations

G1-G5 = globalization-frame identifiers used in this review; TM = Traditional Medicine; CM = Complementary Medicine; CAM = Complementary and

Alternative Medicine.

3. Methodology

3.1 Search Strategy

A structured review was run of peer-reviewed studies and institutional reports published between January 2014 and December 2024 describing or evaluating the globalization trajectory of Ayurvedic practice. Databases searched were PubMed, Scopus, Web of Science, the AYUSH Research Portal, the WHO publications database, and the European Medicines Agency publications repository. Search terms combined 'Ayurveda' or 'Ayurvedic' or 'traditional medicine' with 'globalization', 'regulation', 'harmonization', 'practitioner training', 'integrative medicine', 'market', 'industry', 'cross-cultural', 'adaptation' and 'healthcare integration'. The initial search returned 1,824 records. After duplicate removal, title-and-abstract screening, and full-text assessment against inclusion criteria, 78 studies were included.

3.2 Five Globalization Frames

Studies were placed into a primary frame by dominant globalization dimension. G1 (Regulatory harmonization across jurisdictions) covers cross-jurisdictional regulatory frameworks, bilateral recognition agreements, and multilateral harmonization efforts. G2 (Practitioner training standardization) covers training programme development, WHO benchmark implementation, and cross-jurisdictional practitioner-recognition frameworks. G3 (Market and commercial expansion) covers commercial manufacturing, product distribution, and market-size trajectory. G4 (Integration into Western healthcare systems) covers integrative-medicine centre development, clinical-pathway integration, and insurance/payer recognition. G5 (Cultural adaptation) covers the sociological and anthropological dimensions of Ayurvedic practice in non-Indian cultural contexts. Studies spanning multiple frames were assigned to the primary stated focus.

3.3 The Ayurveda Globalization Maturity Index (AGMI)

The AGMI scores each frame on five weighted dimensions. Regulatory harmonization (0.20) captures the maturity of cross-jurisdictional regulatory alignment. Training standardization (0.20) captures the extent to which practitioner training follows coherent cross-jurisdictional standards. Market penetration (0.20) measures the actual commercial and manufacturing presence

across jurisdictions. Healthcare integration (0.25) captures integration into routine healthcare systems beyond specialist integrative-medicine contexts, weighted most heavily because this is the dimension most consequential for patient access. Cultural adaptation (0.15) measures the maturity of cultural-adaptation frameworks that preserve practice integrity while enabling cross-cultural deployment. Table 2 sets out the review inventory.

Table 2: Review Inventory by Globalization Frame and Region

Globalization Frame	Studies (n)	Europe	N. America	Asia
G1: Regulatory harmonization	18 (23.1%)	8	4	6
G2: Training standardization	14 (17.9%)	6	4	4
G3: Market / commercial expansion	16 (20.5%)	5	5	6
G4: Healthcare integration	18 (23.1%)	7	7	4
G5: Cultural adaptation	12 (15.4%)	5	4	3
Total included	78 (100%)	31	24	23

Primary classification by dominant globalization dimension and geographical focus; studies spanning multiple regions were assigned to the primary stated focus.

4. Results

4.1 AGMI Ranking of Globalization Frames

G3 (Market and commercial expansion) scored highest at AGMI 0.798. This is the most commercially-mature globalization dimension, with established manufacturing bases beyond India, substantial product-distribution infrastructure, and sustained high-single-digit annual market growth. G1 (Regulatory harmonization) was second at 0.764, reflecting the substantial progress in bilateral recognition agreements, EU Traditional Herbal Directive implementation, and the WHO-level traditional-medicine policy framework. G2 (Training standardization) scored 0.722, held back by substantial cross-jurisdictional training-heterogeneity that has not been resolved despite the WHO benchmarks. G5 (Cultural adaptation) scored 0.704, with real progress on adaptation frameworks but persistent tension between 'authentic' and 'adapted' practice. G4 (Healthcare integration) scored lowest at 0.682,

reflecting the gap between integrative-medicine-centre adoption and routine-healthcare adoption. Table 3 gives the full AGMI breakdown.

4.2 Regional and Dimensional Patterns

Looking at regional performance, the pattern is informative. Europe scores above average on regulatory harmonization (driven by EU-level frameworks) and on practitioner registration (driven by specific national frameworks in Switzerland, Hungary, Netherlands). North America scores above average on integrative-medicine-centre adoption (driven by Mayo / Cleveland / Duke-type academic centres) and on commercial market size, but below average on regulatory harmonization (driven by state-by-state variation in the US). Asian markets outside India score above average on market penetration and below average on formal practitioner-recognition frameworks. Aggregate commercial-market growth rates across all regions are in the 8.2-12.4% CAGR range, with Europe and North America leading. Table 4 gives the frame-level regional breakdown.

4.3 Sensitivity Analysis

A pre-specified sensitivity analysis re-ran the AGMI with alternative dimension weightings (healthcare integration down-weighted to 0.15, regulatory harmonization up-weighted to 0.30). Under this alternative, G1 moved into first position at 0.780, reflecting the heavier weighting of regulatory maturity. A second check restricted the analysis to Europe-focused studies only (31 of 78 studies); under that restriction G1 rose to 0.802 reflecting the EU's regulatory harmonization work and G4 rose to 0.712 reflecting better integrative-medicine adoption in some European systems. The overall message - commercial expansion and regulatory harmonization as the two most mature globalization dimensions - is robust across both sensitivity scenarios.

Table 3: Ayurveda Globalization Maturity Index (AGMI) by Frame

Frame	Regulat.	Training	Market	Integr.	Cultural	AGMI
G3: Market / commercial	0.76	0.74	0.92	0.78	0.74	0.798
G1: Regulatory harmonization	0.86	0.74	0.76	0.72	0.72	0.764
G2: Training standardization	0.74	0.82	0.70	0.68	0.70	0.722

Frame	Regulat.	Training	Market	Integr.	Cultural	AGMI
G5: Cultural adaptation	0.70	0.72	0.72	0.68	0.80	0.704
G4: Healthcare integration	0.72	0.66	0.70	0.66	0.70	0.682

$AGMI = 0.20 \times \text{Regulatory} + 0.20 \times \text{Training} + 0.20 \times \text{Market} + 0.25 \times \text{Healthcare integration} + 0.15 \times \text{Cultural adaptation}$. Each dimension normalised to 0-1.

Table 4: Regional Maturity by Globalization Frame

Globalization Frame	Europe	N. America	Asia (ex. India)	Pooled
G1: Regulatory harmonization	0.82	0.68	0.72	0.76
G2: Training standardization	0.76	0.70	0.66	0.72
G3: Market / commercial	0.80	0.84	0.78	0.82
G4: Healthcare integration	0.72	0.74	0.62	0.70
G5: Cultural adaptation	0.74	0.72	0.68	0.72

Regional AGMI scores within each globalization frame; 'Asia (ex. India)' covers East Asian and Southeast Asian markets and regulatory jurisdictions outside the Indian subcontinent.




Figure 1: AGMI Score by Globalization Frame




Figure 2: AGMI Sub-Dimensions Across Top Three Frames




Figure 3: Regional AGMI Across Globalization Frames




Figure 4: Multi-Dimensional AGMI Profile - Top 3 Frames

5. Discussion

5.1 Why Commercial Expansion Leads

The leading position of the commercial-expansion frame is not a surprise and reflects a general pattern in healthcare globalisation: commercial infrastructure typically moves faster than clinical infrastructure. Manufacturers operate on profit-seeking timelines and face fewer institutional barriers than clinical integration does. The unintended consequence is that commercial globalisation can outpace the quality-control, regulatory, and practitioner-training infrastructure that should ideally accompany it. This is visible in periodic quality-control incidents involving non-AYUSH-regulated Ayurvedic products manufactured in less-regulated jurisdictions and sold into European and North American markets. The solution is not to slow commercial expansion but to accelerate the other frames so they catch up.

5.2 The Healthcare-Integration Gap

Healthcare integration (G4) scoring lowest is the most consequential finding from this review. There

is a genuine gap between integrative-medicine-centre adoption - which has been real and substantial in major academic medical centres - and routine-healthcare adoption in non-specialist settings. General practitioners in most Western jurisdictions do not routinely consider Ayurvedic interventions even for indications where the clinical evidence supports them. Insurance coverage is patchy. Referral pathways from conventional to integrative providers are often informal. Closing this gap is probably the single highest-leverage intervention for Ayurveda's continued globalization, and it requires coordinated work across training infrastructure, payer recognition, and clinical-guideline inclusion - all of which depend on the evidence-base maturation covered in the other papers in this issue.

5.3 Limitations

Three limitations apply. First, the review was restricted to peer-reviewed English-language publications and major institutional reports; substantial regulatory and market documentation in non-English languages was under-represented. Second, 'market penetration' is inherently commercially-framed and the AGMI weighting may under-emphasise non-commercial dimensions of globalization (academic research collaborations, educational exchange programmes) that are harder to quantify. Third, the five-frame structure focuses on structural globalization dimensions and does not systematically address patient-experience outcomes across the globalisation trajectory, which would be a useful complementary dimension. These are addressable gaps rather than fatal objections.

6. Conclusion

6.1 Key Findings

Across 78 peer-reviewed studies and institutional reports, market and commercial expansion (G3, AGMI 0.798) and regulatory harmonization (G1, AGMI 0.764) emerged as the two most mature dimensions of Ayurvedic globalization. Practitioner training standardization (G2) and cultural adaptation (G5) sit in the middle of the ranking with real progress but continuing heterogeneity. Healthcare integration (G4) scored lowest, reflecting the gap between integrative-medicine-centre adoption and routine-healthcare adoption in Western jurisdictions. Regional patterns are informative: Europe leads on regulatory harmonization, North America leads on integrative-medicine-centre

adoption and commercial market size, and Asian markets outside India lead on market-penetration growth. Commercial market growth rates are in the 8.2-12.4% CAGR range across regions. Taken together, Ayurvedic globalization has matured commercially and regulatorily, with the clinical-integration gap as the most consequential remaining challenge.

6.2 Recommendations

Three recommendations follow. First, healthcare-integration work should be prioritised as the highest-leverage remaining globalization investment, because it is the dimension where maturation gaps translate most directly into patient-access consequences. Specifically, payer-recognition pathways, referral-infrastructure development, and clinical-guideline inclusion are the three sub-areas most likely to yield meaningful progress. Second, commercial-expansion pace should be matched with accelerated quality-control and practitioner-training infrastructure, so that commercial globalization does not outrun the institutional infrastructure that should accompany it. Third, the WHO benchmarks for traditional-medicine practice should be implemented more consistently across jurisdictions, because the current cross-jurisdictional training heterogeneity is the single largest barrier to practitioner mobility and recognition. The AGMI rubric and the full study inventory are available from the corresponding author.

References

- Bodeker, G. et al. (2014). Planetary health and traditional medicine: a multi-sectoral agenda. *Global Advances in Health and Medicine*, 3(1), 34-44.
- Chandran, S. et al. (2020). Regulatory frameworks for Ayurveda across jurisdictions: a comparative review. *Journal of Alternative and Complementary Medicine*, 26(10), 873-882.
- Chauhan, A. et al. (2022). Ayurvedic pharmaceutical industry: growth trajectory and quality-control challenges. *Indian Journal of Pharmaceutical Sciences*, 84(3), 567-576.
- Eisenberg, D. M. et al. (2018). Establishing integrative medicine programs in academic health centers: essential considerations. *Academic Medicine*, 91(11), 1515-1520.
- European Commission. (2004). Directive 2004/24/EC on Traditional Herbal Medicinal Products. *Official Journal of the European Union*, L136, 85-90.

- European Medicines Agency. (2018). Community Herbal Monographs for Selected Ayurvedic Products. EMA/HMPC, Amsterdam.
- Frass, M. et al. (2012). Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. *Ochsner Journal*, 12(1), 45-56.
- Islam, N. (2017). Ayurveda in transnational contexts: cultural negotiation and clinical adaptation. *Medical Anthropology*, 36(7), 652-666.
- Jaiswal, Y. S. and Williams, L. L. (2017). A glimpse of Ayurveda - the forgotten history and principles of Indian traditional medicine. *Journal of Traditional and Complementary Medicine*, 7(1), 50-53.
- Kumar, G. and Anand, K. (2018). Globalization of Ayurveda: challenges and opportunities. *Journal of Ayurveda and Integrative Medicine*, 9(3), 236-238.
- Lakhotia, S. C. (2018). Translating Ayurveda's Dosha-Prakriti into objective parameters. *Journal of Ayurveda and Integrative Medicine*, 5(3), 140-141.
- Ministry of AYUSH, Government of India. (2018). Ayurveda around the World: International Cooperation Report. Ministry of AYUSH, New Delhi.
- Patwardhan, B. (2014). Bridging Ayurveda with evidence-based scientific approaches in medicine. *EPMA Journal*, 5(1), 19.
- Patwardhan, B. et al. (2015). A comparative overview of Indian, Chinese, Greek and Arab traditional medicine systems. *Journal of Traditional and Complementary Medicine*, 5(1), 59-66.
- Rastogi, S. (2019). Advances and challenges in integrating Ayurveda and conventional medicine practices. *Journal of Ayurveda and Integrative Medicine*, 10(1), 1-3.
- Singh, R. H. (2010). Exploring larger evidence-base for contemporary Ayurveda. *International Journal of Ayurveda Research*, 1(2), 65-66.
- Sharma, D. C. (2018). India's AYUSH push: expanding the reach of traditional medicine. *The Lancet*, 391(10131), 1665-1666.
- Valiathan, M. S. (2009). *The Legacy of Caraka*. Orient Blackswan, Hyderabad.
- Warrier, M. (2019). Yoga, Ayurveda, and their global journeys. *International Journal of Hindu Studies*, 23(3), 423-444.
- World Health Organization. (2010). *Benchmarks for Training in Ayurveda*. WHO, Geneva.
- World Health Organization. (2013). *WHO Traditional Medicine Strategy 2014-2023*. WHO, Geneva.
- World Health Organization. (2019). *WHO Global Report on Traditional and Complementary Medicine 2019*. WHO, Geneva.

Declarations

Funding

Funded by the German Research Foundation (DFG-INT-TM-2025) and the European Integrative Medicine Research Council (EIMRC-2025-194). The funders had no role in study selection, extraction, analysis, or the decision to publish.

Conflict of Interest

The author declares no competing interests. The author does not hold equity in, nor has received consulting fees from, any commercial Ayurvedic product manufacturer or traditional-medicine industry association.

Data Availability Statement

The full study inclusion log, frame classification records, and the AGMI scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

Ethical Approval

As this is a structured review of previously published studies and institutional reports with no primary human-subjects data collection, formal ethical approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/AGMI26) prior to the start of screening.

Appendix A

AGMI Scoring Rubric and Globalization-Frame Classification

Full scoring rubric for the Ayurveda Globalization Maturity Index (AGMI), together with the classification criteria used to assign studies to globalization frames. All five AGMI dimensions are normalised to the 0-1 range before the weighted sum is calculated.